Related Experiment Videos
Outcomes for assessment of symptomatic and stabilization/disease modifying drugs
1Alzheimer Disease Research Unit, McGill Centre for Studies in Aging, Verdun, Quebec, Canada.
Abstract:
The safety and efficacy of current symptomatic drugs for AD was established using parallel groups taking different doses of active drugs vs placebo over three to twelve months, whereas drugs with potential stabilizing/disease modifying effects are being tested by adding new compounds or placebo to standard symptomatic drugs over 12 to 18 months. Delaying progression to disease milestones may offer additional validity to these studies. It is unclear if biological and neuroimaging markers will add to the clinical evidence.
Related Concept Videos
Drug Therapy
Antianxiety Medications
Psychosis: Goals of Pharmacotherapy
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring: Overview and Classification
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents